Clinical Trial Update: A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

A Phase 2 trial of Telisotuzumab vedotin in adults with advanced/metastatic non-squamous non-small cell lung cancer was terminated, with results posted in 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Telisotuzumab Vedotin (Telisotuzumab Vedotin)

Snippet

Sponsor: AbbVie | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2025-10-24